Agios Pharmaceuticals (AGIO) had its price target raised by JPMorgan Chase & Co. from $31.00 to $36.00. They now have a "neutral" rating on the stock.
Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ET
Agios Pharmaceuticals (AGIO) had its price target raised by The Goldman Sachs Group, Inc. from $28.00 to $32.00. They now have a "neutral" rating on the stock.
Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky
Insider Sells AGIO Shares Worth $82,000 -- But Context Is Everything [Yahoo! Finance]